Biohaven presents update on Phase 1 single ascending dose study for BHV-1300

In a regulatory filing, Biohaven disclosed that David Spiegel, M.D. Ph.D., inventor of Biohaven’s MoDE technology and Professor of Chemistry at Yale University, will present an update on Biohaven’s degrader platform and summary of progress to date in the Phase 1 single ascending dose, or “SAD,” study for BHV-1300 at the ABI Conference 2024 in Cambridge, United Kingdom starting April 15. A copy of the presentation was disclosed by the company in the filing with the SEC.